Testosterone Enanthate Dose Adjustments for South Asian Patients

Why South Asian Men Need a Different Dosing Approach

South Asian men carry a distinct cardiometabolic risk profile that changes how testosterone enanthate should be prescribed, titrated, and monitored. Standard dosing protocols were developed from trials enrolling predominantly white men, and applying those protocols without adjustment ignores measurable biological differences in this population.

The Cardiometabolic Gap

The INTERHEART study (N=27,098 across 52 countries) demonstrated that South Asians experience first myocardial infarction at a median age roughly 5 years younger than other populations, with abdominal adiposity and dyslipidemia contributing disproportionately to that risk [1]. Testosterone therapy increases erythropoiesis and can shift lipid ratios. In a population already predisposed to earlier cardiovascular events, these effects demand closer surveillance.

Metabolic Syndrome at Lower BMI

The WHO and the International Diabetes Federation recognize that South Asian populations develop insulin resistance and type 2 diabetes at a lower BMI threshold (BMI 23 vs. 25 for European populations) [2]. The UK Biobank cohort confirmed that South Asian participants had a 2- to 4-fold higher incidence of type 2 diabetes compared with white British participants at every BMI category [3]. Because low testosterone and metabolic syndrome share a bidirectional relationship, clinicians must distinguish whether hypogonadal symptoms reflect true androgen deficiency or metabolic dysfunction (or both) before committing to long-term TRT.

What the T-Trials Showed

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older with testosterone below 275 ng/dL, found that testosterone gel raised hemoglobin, improved sexual function, and increased coronary artery plaque volume on CT angiography at 12 months [4]. South Asian men were underrepresented in TTrials enrollment. That data gap means extrapolating cardiovascular safety findings from TTrials to this population requires caution and tighter monitoring intervals.

Pharmacogenomic Factors That Influence Testosterone Metabolism

Genetic variation in androgen-metabolizing enzymes creates measurable differences in how South Asian men process exogenous testosterone. Understanding these variants allows clinicians to anticipate atypical drug levels and adjust accordingly.

UGT2B17 Deletion Polymorphism

The enzyme UGT2B17 catalyzes the glucuronidation of testosterone and its metabolites for urinary excretion. A homozygous deletion of the UGT2B17 gene (del/del genotype) is present in approximately 60 to 80% of East Asian men and an estimated 20 to 30% of South Asian men, compared with roughly 10% of European men [5]. Men carrying the del/del genotype clear testosterone glucuronide more slowly. The clinical effect: for a fixed dose, serum testosterone may run higher and longer in del/del carriers. PharmGKB classifies UGT2B17 as a pharmacogene with "very important" status for androgen metabolism [6].

SRD5A2 Variants and DHT Conversion

The 5-alpha reductase type 2 enzyme (encoded by SRD5A2) converts testosterone to dihydrotestosterone (DHT). Certain SRD5A2 polymorphisms (notably V89L) are more prevalent in Asian populations and associated with reduced 5-alpha reductase activity [7]. Lower DHT conversion could blunt androgenic effects on the prostate while also reducing scalp and skin androgenization. This does not necessarily warrant a dose increase; it means the clinical response profile may differ from what clinicians expect.

SHBG and Free Testosterone

Several cohort analyses, including data from the Study of Health in Pomerania and the European Male Ageing Study, have shown that South Asian men tend to have lower sex hormone-binding globulin (SHBG) levels than white European men [8]. Lower SHBG means a greater fraction of total testosterone is bioavailable. A South Asian man with a total testosterone of 350 ng/dL may have a free testosterone equivalent to a European man at 450 ng/dL. Checking calculated free testosterone or bioavailable testosterone, not just total, is non-negotiable in this population.

Recommended Starting Dose and Titration Protocol

The Endocrine Society's 2018 clinical practice guideline recommends testosterone enanthate 75 to 100 mg IM weekly or 150 to 200 mg IM every 2 weeks for adult men with confirmed hypogonadism [9]. For South Asian men with elevated cardiometabolic risk, a modified approach is safer.

Initial Dosing

Start at 100 mg IM every 7 to 10 days. This lower-frequency, lower-dose approach reduces peak-to-trough swings that drive erythrocytosis and estradiol spikes. Avoid the common "200 mg every 14 days" regimen; the high peak followed by a deep trough worsens mood instability and amplifies hematocrit surges.

Titration Schedule

Draw trough testosterone (morning of injection day) at week 8. Target a trough of 400 to 600 ng/dL. If the trough sits below 400 ng/dL and symptoms persist, increase by 25 mg per injection. If the trough exceeds 600 ng/dL or hematocrit is above 50%, reduce by 25 mg.

When to Reconsider TRT Entirely

If a South Asian patient presents with borderline-low testosterone (250 to 350 ng/dL), BMI above 27, HbA1c above 5.7%, and no pituitary pathology, the hypogonadism may be functional. Weight loss of 5 to 10% of body weight can raise endogenous testosterone by 50 to 100 ng/dL. The EMAS (European Male Ageing Study, N=3,369) found that obesity and metabolic syndrome accounted for more testosterone decline than aging itself in men under 70 [8]. Treat the metabolic driver before defaulting to lifelong TRT.

Cardiovascular Risk Monitoring on TRT

South Asian men on testosterone enanthate require a cardiovascular monitoring protocol that is more aggressive than what general guidelines suggest. The TRAVERSE trial (N=5,246) established that testosterone replacement in men aged 45 to 80 with cardiovascular risk did not increase the composite rate of major adverse cardiovascular events (MACE) over a median 33 months compared with placebo [10]. That trial, though reassuring for the general population, enrolled only 3.6% Asian participants.

Hematocrit and Polycythemia

Testosterone stimulates erythropoietin. The Endocrine Society guideline sets a hematocrit threshold of 54% for dose reduction or withholding [9]. For South Asian men, especially those living at lower altitudes with no physiologic reason for elevated hematocrit, a more conservative ceiling of 52% is reasonable.

Check complete blood count (CBC) at baseline, 6 weeks, 3 months, 6 months, and every 6 months thereafter. If hematocrit exceeds 52%, reduce the dose by 25 mg per injection and recheck in 4 weeks. If hematocrit exceeds 54%, hold therapy entirely, investigate for sleep apnea, and consider therapeutic phlebotomy.

Lipid Panel Shifts

Exogenous testosterone typically lowers HDL-cholesterol by 5 to 15%. South Asian men already carry a lipid phenotype characterized by low HDL, elevated triglycerides, and high lipoprotein(a) [1]. A 10% HDL drop in a man whose baseline HDL is 38 mg/dL is clinically different from the same percentage drop in a man starting at 55 mg/dL.

Check a fasting lipid panel at baseline, 3 months, and 6 months. If HDL falls below 30 mg/dL, reassess the risk-benefit calculation with the patient. Consider concurrent statin therapy per ACC/AHA guidelines if the 10-year ASCVD risk score (using the pooled cohort equation with South Asian ethnicity factored in) exceeds 7.5%.

Blood Pressure and Fluid Retention

Testosterone can cause mild sodium and water retention. In South Asian men with pre-existing hypertension (prevalence is roughly 30% in South Asian adults in the US per MASALA study data) [11], monitor blood pressure at every visit for the first 6 months.

Estradiol Management in South Asian Men on TRT

Aromatase (CYP19A1) converts testosterone to estradiol in adipose tissue. South Asian men with visceral adiposity, even at normal or mildly elevated BMI, may aromatize testosterone at higher rates than their total body fat percentage would predict.

Monitoring Protocol

Measure serum estradiol (sensitive LC-MS/MS assay, not immunoassay) at every trough lab draw. Target range: 20 to 40 pg/mL. Levels above 50 pg/mL may cause gynecomastia, water retention, and mood changes.

Intervention Thresholds

If estradiol exceeds 50 pg/mL on two consecutive draws, first reduce the testosterone dose by 25 mg. If levels remain elevated despite dose reduction, and the patient is symptomatic, a low-dose aromatase inhibitor (anastrozole 0.5 mg twice weekly) can be considered, though this is off-label and the Endocrine Society recommends against routine AI use with TRT [9]. Weight loss remains the most effective long-term intervention for estradiol control.

PSA, Prostate Safety, and South Asian-Specific Data

The Endocrine Society recommends checking PSA at baseline, 3 to 6 months, and then per age-appropriate screening guidelines [9]. South Asian men have lower age-standardized prostate cancer incidence than white men (GLOBOCAN 2020 data: India's age-standardized rate is 4.0 per 100,000 vs. 73.0 per 100,000 in the US) [12].

What This Means for Monitoring

Lower baseline incidence does not eliminate risk. A PSA rise of more than 1.4 ng/mL within 12 months of starting TRT, or any PSA above 4.0 ng/mL, warrants urology referral regardless of ethnicity. The SRD5A2 V89L variant, more common in South Asian men, may blunt DHT-mediated prostate growth, but no trial has confirmed this as a clinically protective factor during exogenous testosterone use.

Diabetes, Insulin Resistance, and the Testosterone Connection

The relationship between low testosterone and type 2 diabetes is well-documented. The T4DM trial (N=1,007 men with impaired glucose tolerance or newly diagnosed T2DM) showed that testosterone undecanoate plus lifestyle intervention reduced the proportion of men with type 2 diabetes at 2 years by 40% compared with lifestyle intervention plus placebo [13].

Why This Matters More in South Asian Men

South Asian men develop type 2 diabetes approximately 10 years earlier than European-descent men, often at a BMI of 23 to 25 [2]. The MASALA study (Mediators of Atherosclerosis in South Asians Living in America, N=906) found that 23% of South Asian American participants had diabetes, compared with 6% of the general US population at matched age ranges [11].

Practical Application

If a South Asian man with borderline hypogonadism also has prediabetes (HbA1c 5.7 to 6.4%), initiating testosterone may improve insulin sensitivity. But this benefit only holds alongside lifestyle modification. Monitor HbA1c and fasting glucose at baseline and every 3 months for the first year. Do not use testosterone as a substitute for metformin, dietary change, or exercise in patients who meet criteria for pharmacologic diabetes prevention.

Drug Interactions Relevant to South Asian Patients

South Asian men on TRT are frequently co-prescribed medications for cardiometabolic conditions. Several interactions deserve attention.

Statins

Testosterone enanthate does not have a direct pharmacokinetic interaction with atorvastatin or rosuvastatin. The concern is pharmacodynamic: both testosterone and statins affect hepatic lipid metabolism. Monitor liver function (ALT, AST) at 3 and 6 months after starting TRT if the patient is on a statin. South Asian men also show higher rates of statin-associated myalgia in some registry analyses, so track CK levels if muscle symptoms arise [14].

Metformin

Metformin and testosterone can both improve insulin sensitivity. No dose adjustment is needed for either drug. The combination is reasonable in hypogonadal South Asian men with concurrent prediabetes or type 2 diabetes.

Anticoagulants and Antiplatelets

Testosterone-driven erythrocytosis increases blood viscosity. In South Asian men taking aspirin or clopidogrel for secondary cardiovascular prevention, the hematocrit ceiling of 52% becomes even more clinically relevant. Polycythemia in the setting of antiplatelet therapy creates a complex thrombotic risk profile.

Long-Term Monitoring Checklist

The following schedule applies specifically to South Asian men on testosterone enanthate. It builds on the Endocrine Society 2018 guideline [9] with population-specific adjustments.

| Test | Baseline | 6 Weeks | 3 Months | 6 Months | Every 6 Months | |------|----------|---------|----------|----------|-----------------| | Total + free testosterone (trough) | Yes | No | Yes | Yes | Yes | | CBC with hematocrit | Yes | Yes | Yes | Yes | Yes | | Fasting lipid panel | Yes | No | Yes | Yes | Annually | | HbA1c / fasting glucose | Yes | No | Yes | Yes | Annually | | Estradiol (sensitive) | Yes | No | Yes | Yes | Yes | | PSA | Yes | No | Yes | No | Per screening guidelines | | Hepatic panel (ALT, AST) | Yes | No | Yes | Yes | Annually | | Blood pressure | Every visit | Every visit | Every visit | Every visit | Every visit |

The 6-week CBC is the most commonly skipped draw. It is also the draw most likely to catch early erythrocytosis before it becomes dangerous. Do not skip it.

Fertility Preservation Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis and can reduce sperm counts to azoospermic levels within 3 to 6 months. South Asian cultural contexts often involve family planning considerations at the time of TRT initiation.

If fertility preservation is desired, consider alternatives to testosterone enanthate: clomiphene citrate 25 to 50 mg daily (off-label), enclomiphene, or human chorionic gonadotropin (hCG) 1,500 to 3,000 IU subcutaneously twice weekly. These options maintain or improve spermatogenesis while raising serum testosterone. Discuss reproductive goals before the first injection.

The American Urological Association states that testosterone therapy should not be initiated in men actively trying to conceive [15]. If a patient has already started TRT and wishes to restore fertility, recovery of spermatogenesis after cessation typically takes 6 to 12 months but can take up to 24 months.